Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor
Status:
Completed
Trial end date:
2017-12-11
Target enrollment:
Participant gender:
Summary
This is a Phase 1, single-center, fixed-sequence, open label, drug-drug interaction study of
the effect of multiple daily doses of oral itraconazole 200 mg, a strong inhibitor of CYP3A,
given with mifepristone 900 mg QD, in healthy male subjects, where all drug administrations
are given after a meal.